🇺🇸 FDA
Patent

US 10815206

RIP1 inhibitory compounds and methods for making and using the same

granted A61PA61P29/00A61P35/00

Quick answer

US patent 10815206 (RIP1 inhibitory compounds and methods for making and using the same) held by Rigel Pharmaceuticals, Inc. expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61P, A61P29/00, A61P35/00, A61P37/02